The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Alzheimer Disease, Early Onset
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
-
MD First Research - Chandler, Chandler, Arizona, United States, 85226-3732
Gilbert Neurology, Gilbert, Arizona, United States, 85297-0441
Xenoscience Inc. - 21st Century Neurology, Phoenix, Arizona, United States, 85004
Perseverance Research Center (PRC), Scottsdale, Arizona, United States, 85253-4550
Imaging Endpoints LLC, Scottsdale, Arizona, United States, 85258-4595
Center for Neurosciences - Tucson, Tucson, Arizona, United States, 85718-6522
The Banner Alzheimer's Institute - Tucson, Tucson, Arizona, United States, 85718-6632
Pharmacology Research Institute (PRI) - Encino, Encino, California, United States, 91316-1511
Neurology Center of North Orange County, Fullerton, California, United States, 92835-1040
Irvine Center for Clinical Research, Irvine, California, United States, 92614-9403
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
50 Years to 80 Years
ALL
No
Bristol-Myers Squibb,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2027-11-16